Advanced search
Publication Cover
Current Medical Research and Opinion Volume 26, 2010 - Issue 10
Submit an article Journal homepage
617
Views
21
CrossRef citations to date
0
Altmetric
Brief Report

The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease

Martin R. Farlow Indiana University School of Medicine, Indianapolis, Indiana, USACorrespondence[email protected]
,
George Grossberg St Louis University School of Medicine, St Louis, Missouri, USA
,
Serge Gauthier McGill Centre for Studies in Aging, Verdun, Québec, Canada
,
Xiangyi Meng Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
&
Jason T. Olin Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
Pages 2441-2447 | Accepted 04 Aug 2010, Published online: 10 Sep 2010

Citations (21)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Sirasa Ruangritchankul, Prawat Chantharit, Sahaphume Srisuma & Leonard C Gray. (2021) Adverse Drug Reactions of Acetylcholinesterase Inhibitors in Older People Living with Dementia: A Comprehensive Literature Review. Therapeutics and Clinical Risk Management 17, pages 927-949.
Read now
Rachel A. Nieto, William James Deardorff & George T. Grossberg. (2016) Efficacy of rivastigmine tartrate, transdermal system, in Alzheimer’s disease. Expert Opinion on Pharmacotherapy 17:6, pages 861-870.
Read now
Serge Gauthier, Alain Robillard, Sharon Cohen, Sandra Black, John Sampalis, Diane Colizza, Frederica de Takacsy & Robyn Schecter. (2013) Real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer’s disease: the EMBRACE study. Current Medical Research and Opinion 29:8, pages 989-1000.
Read now

Articles from other publishers (18)

Kevin Nguyen, Heidi Hoffman, Binu Chakkamparambil & George T Grossberg. (2021) Evaluation of rivastigmine in Alzheimer's disease. Neurodegenerative Disease Management 11:1, pages 35-48.
Crossref
A.N. Bogolepova, E.E. Vasenina, N.A. Gomzyakova, E.I. Gusev, N.G. Dudchenko, A.Yu. Emelin, N.M. Zalutskaya, R.I. Isaev, Yu.V. Kotovskaya, O.S. Levin, I.V. Litvinenko, V.Yu. Lobzin, M.Yu. Martynov, E.A. Mkhitaryan, G.N. Nikolay, E.I. Palchikova, O.N. Tkacheva, M.A. Cherdak, A.S. Chimagomedova & N.N. Yakhno. (2021) Clinical Guidelines for Cognitive Disorders in Elderly and Older Patients. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 121:10, pages 6.
Crossref
Yusuke Fukui, Nozomi Hishikawa, Jin Ichinose, Kota Sato, Yumiko Nakano, Ryuta Morihara, Yasuyuki Ohta, Toru Yamashita & Koji Abe. (2017) Different clinical effect of four antidementia drugs for Alzheimer's disease patients depending on white matter severity. Geriatrics & Gerontology International 17:11, pages 1991-1999.
Crossref
Zhen-Xin Zhang, Zhen Hong, Yan-Ping Wang, Li He, Ning Wang, Zhong-Xin Zhao, Gang Zhao, Lan Shang, Marianne Weisskopf, Francesca Callegari & Christine Strohmaier. (2016) Rivastigmine Patch in Chinese Patients with Probable Alzheimer's disease: A 24-week, Randomized, Double-Blind Parallel-Group Study Comparing Rivastigmine Patch (9.5 mg/24 h) with Capsule (6 mg Twice Daily). CNS Neuroscience & Therapeutics 22:6, pages 488-496.
Crossref
Richard S. Isaacson, Steven Ferris, Drew M. Velting & Xiangyi Meng. (2015) Cognitive Efficacy (SIB) of 13.3 Versus 4.6 mg/24 h Rivastigmine Patch in Severe Alzheimer’s Disease. American Journal of Alzheimer's Disease & Other Dementiasr 31:3, pages 270-277.
Crossref
Kosuke Matsuzono, Kota Sato, Syoichiro Kono, Nozomi Hishikawa, Yasuyuki Ohta, Toru Yamashita, Kentaro Deguchi, Yumiko Nakano & Koji Abe. (2015) Clinical Benefits of Rivastigmine in the Real World Dementia Clinics of the Okayama Rivastigmine Study (ORS). Journal of Alzheimer's Disease 48:3, pages 757-763.
Crossref
Jacqueline S Birks, Lee-Yee Chong & John Grimley Evans. (2015) Rivastigmine for Alzheimer's disease. Cochrane Database of Systematic Reviews.
Crossref
William James Deardorff, Eliahu Feen & George T. Grossberg. (2015) The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer’s Disease. Drugs & Aging 32:7, pages 537-547.
Crossref
Martin R. Farlow, Carl H. Sadowsky, Drew M. Velting, Xiangyi Meng & M. Zahur Islam. (2015) Evaluating Response to High-Dose 13.3 mg/24 h Rivastigmine Patch in Patients with Severe Alzheimer's Disease. CNS Neuroscience & Therapeutics 21:6, pages 513-519.
Crossref
G. Alva, J. L. Cummings, J. E. Galvin, X. Meng & D. M. Velting. (2015) Skin reactions at the application site of rivastigmine patch (4.6 mg/24 h, 9.5 mg/24 h or 13.3 mg/24 h): a qualitative analysis of clinical studies in patients with Alzheimer's disease. International Journal of Clinical Practice 69:5, pages 518-530.
Crossref
Jacqueline S Birks & John Grimley Evans. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Martin R. Farlow, George T. Grossberg, Carl H. Sadowsky, Xiangyi Meng & Drew M. Velting. (2015) A 24-Week, Open-Label Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of 13.3 mg/24 h Rivastigmine Patch in Patients With Severe Alzheimer Disease. Alzheimer Disease & Associated Disorders 29:2, pages 110-116.
Crossref
E. E. Vasenina & O. S. Levin. (2015) Characteristics of the clinical picture and treatment of moderate or severe Alzheimer’s disease. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 115:6. Vyp. 2, pages 17.
Crossref
Joseph L Micca, James E Galvin, Drew M Velting & Xiangyi Meng. (2014) Efficacy of 13.3 mg/24 h versus 4.6 mg/24 h rivastigmine patch on activities of daily living in severe Alzheimer’s disease. SAGE Open Medicine 2, pages 205031211456156.
Crossref
Martin R. Farlow, George T. Grossberg, Carl H. Sadowsky, Xiangyi Meng & Monique Somogyi. (2013) A 24‐Week, Randomized, Controlled Trial of Rivastigmine Patch 13.3 mg/24 h Versus 4.6 mg/24 h in Severe Alzheimer's Dementia. CNS Neuroscience & Therapeutics 19:10, pages 745-752.
Crossref
Alessandra Clodomiro, Pietro Gareri, Gianfranco Puccio, Francesca Frangipane, Roberto Lacava, Alberto Castagna, Valeria Graziella Laura Manfredi, Rosanna Colao & Amalia Cecilia Bruni. (2013) Somatic comorbidities and Alzheimer’s disease treatment. Neurological Sciences 34:9, pages 1581-1589.
Crossref
Sohita Dhillon. (2011) Rivastigmine Transdermal Patch. Drugs 71:9, pages 1209-1231.
Crossref
Rüdiger Hardeland. (2011) Cognitive Enhancers in Moderate to Severe Alzheimer's Disease. Clinical Medicine Insights: Therapeutics 3, pages CMT.S6344.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.